LONDON, Sept. 18 /PRNewswire/ -- IDIS, the world leader in the
development and implementation of Named Patient Programs (NPPs), will
sponsor the first-of-its-kind conference on pre-launch access to drugs in
Baltimore, MD, on October 22-23. This conference will bring together
industry experts to present and exchange information on programs that
enable patients with unmet medical needs to get access to drugs in the
pre-launch phase. Industry leaders will discuss the fundamentals of
US-based expanded access programs (EAPs) and global named patient programs,
the best strategies for development of such programs, the optimal timing
for programs, and their overall management.
Internet access to information about drugs in late-stage clinical
trials or approvals in certain countries has created a more informed and
empowered population of patients who are taking a more aggressive approach
to their health. This has brought about an increased demand for access to
pre-launch drugs amongst patients when all other therapeutic options have
been exhausted. Fortunately, government sanctioned EAPs and NPPs are in
place to help drug developers respond to such requests.
This conference, produced by the Center for Business Intelligence
(CBI), is geared towards pharmaceutical and biotechnology company decision
makers from global brand groups, regulatory, medical affairs,
supply/logistics and other functions involved in patient access programs.
The conference will provide a forum by which these companies can learn how
these programs benefit patients as well as the sponsoring company, as well
as the best way to execute these programs to ensure they are conducted in a
manner consistent with regulations that vary by country. It will also offer
extensive opportunities for networking and discussion with senior policy
and decision makers.
Registration is currently being accepted at:
Additional information about the conference is available at:
Founded in 1987, IDIS is the global leader in the development,
implementation, and management of strategic solutions that provide access
to unlicensed medicines across global markets via Named Patient Programs.
Pharmaceutical and biotechnology companies of all sizes partner with IDIS
to provide patients with genuine, unmet medical need access to potentially
IDIS is headquartered near central London.
Visit the IDIS website at http://www.idispharma.com .
About CBI (www.cbinet.com)
A subsidiary of Advanstar Communications, CBI Research, Inc. is
dedicated to developing market-driven, unbiased conferences in
pharmaceuticals\biotech, medical devices, risk and insurance and managed
care markets. CBI Research, Inc. offers conferences and summits that serve
senior executives and government officials by providing a unique platform
for highly focused content and presentation.
For further information on IDIS contact:
Feinstein Kean Healthcare